A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

NCT01531972 ↗

Phase 1 Completed 30 enrolled Sumitomo Pharma America, Inc.

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This is an open-label study investigating the relationship between SEP-228432 and SEP-228431 (the active metabolite of SEP-228432) plasma concentrations, SERT occupancy, and DAT occupancy, both measured by SPECT imaging.

Timeline

Start: 2012-02
Primary completion: 2012-05
Completion: 2012-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SEP 228432	Unknown	200 mg	Oral

Indications

No indication recorded.